User tried microneedling with min and fin for hair loss, experienced inflamed scalp and dandruff. Recommends proper disinfection of microneedler to avoid issues.
The conversation discusses experiences with hair loss treatments containing RootBioTec and Anagain. Users share their results and compare these treatments to Minoxidil, finasteride, and RU58841.
Testosterone can still cause hair loss even when DHT is blocked by dutasteride, especially if hair follicles are sensitive. Topical treatments like RU58841 or pyrilutamide may help, but their long-term effectiveness is uncertain compared to dutasteride.
Parabens in Minoxidil are a concern for some users due to potential health risks. The conversation discusses the presence of methylparaben and propylparaben in a specific Minoxidil brand, Ylox.
Topical Minoxidil and RU58841 can make hair look brittle and thin, possibly due to the propylene glycol in their solutions. Some users experience side effects like heart palpitations with RU58841, while others have no issues.
Probiotics like L. reuteri ATCC PTA 6475 and B. longum BB536 may improve hair growth and density by reducing inflammation and reversing DHT damage. The user is trialing these probiotics personally, ordering them from the U.S. to Canada, and plans to continue if no adverse effects occur.
The conversation is about whether the phase 2 results for pyrilutamide, a potential hair loss treatment, were presented at a dermatology convention and inquiries about the completion of phase 3 trials. Specific treatments mentioned include pyrilutamide.
PP405 targets hair follicle stem cells differently than exercise-induced lactate, suggesting exercise alone may not replicate its benefits. Minoxidil and finasteride are recommended alongside exercise for hair regrowth, with additional suggestions like spicy food and infrared exposure.
An 18-year-old experienced severe side effects, including heart palpitations and high blood pressure, after using RU58841 once, leading to a referral to cardiology for suspected left ventricular hypertrophy. The user regrets using RU58841 and seeks advice on recovery, while others suggest preexisting conditions or genetic predispositions may be factors.
A 19-year-old male switched from finasteride and minoxidil to dutasteride due to continued hair thinning and is experiencing increased nipple sensitivity and a small lump, raising concerns about gynecomastia. Suggestions include slowing the transition, checking hormone levels, and considering an aromatase inhibitor.
The conversation is about concerns and advice regarding microneedling for hair loss, with potential risks like chronic inflammation, scarring, and folliculitis. The user has been using minoxidil, finasteride, and stemoxydine with good results and is considering adding microneedling, with recommendations for using a dermastamp or pen.
Rating treatments for hair loss, with the help of GPT-4, according to efficacy, evidence and tolerability; a combination of chemicals from research papers, custom compounds, and some suggestions from other users were included.
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.
A human trial involving the use of Verteporfin as a treatment for hair loss, which has been ongoing for 119 days with an update on its progress. Treatments such as Minoxidil, Finasteride and RU58841 have also been discussed.
The conversation discusses managing gynecomastia symptoms potentially caused by finasteride use, with treatments including reducing finasteride dosage, using DIM, ashwagandha, tamoxifen, epistane, and arimistane. Users share experiences and advice on balancing testosterone and estrogen levels to address symptoms.
The conversation discusses concerns about oral minoxidil potentially aging the face by affecting collagen, questioning its systemic effects. The user has successfully used topical minoxidil for years and is hesitant to switch to oral minoxidil.
The user stopped using finasteride after two weeks due to gynecomastia symptoms and shared blood work results questioning if they indicate a cause for the side effects. The user is considering restarting finasteride and seeking advice on their blood work levels in relation to gynecomastia.
The conversation discusses updates on hair loss treatments, specifically GT20029, PP405, and a rumored injectable peptide from UT. GT20029 is seen as a promising treatment expected within 5-7 years.
The conversation is about the potential availability of GT20029 on the black market and whether users would try it. Participants advise waiting for phase 3 trial results to ensure safety and efficacy.
Tretinoin may worsen hair loss by inducing premature hair follicle regression. It can be used with minoxidil to increase absorption but should not be used alone.
Hair loss treatments like Minoxidil, finasteride, and potential mRNA therapies are discussed. There is skepticism about targeting specific genes due to the complex genetic nature of hair loss.
Microneedling can potentially damage hair if not done carefully, with suggestions to press instead of roll and to use a pen. It's recommended to microneedle once a week at 1.5mm and wait 24 hours before applying Minoxidil to avoid unwanted absorption.
A young man faces severe hair loss in his early 20s, using treatments like dutasteride and minoxidil with little success, impacting his self-esteem and relationships. He considers hair systems and therapy as potential solutions.
The conversation is about a user trying a new hair loss treatment, Ruxolitinib, alongside their existing regimen of finasteride, minoxidil, ketoconazole shampoo, and microneedling. They plan to apply Ruxolitinib to their temples daily for 1-2 months.
The user has tried various hair loss treatments including topical minoxidil, oral finasteride, oral dutasteride, oral minoxidil, and exosome therapy, but none have been effective. They suspect trichodynia might be preventing these treatments from working.
The user experienced hair thinning from chromium and alpha lipoic acid supplements, which stopped after discontinuing them. Someone mentioned this could be telogen effluvium, a temporary condition.
Micronutrient testing and deficiencies related to hair loss, particularly androgenetic alopecia (AGA). Discussion includes the impact of iron, selenium, zinc, copper, folate, B12, vitamin E, vitamin D, amino acids, and fatty acids, alongside treatments like dutasteride or finasteride.
The conversation is about using microneedling for hair loss treatment, including questions on disinfection and post-treatment care. The user mentions using oral minoxidil and finasteride, and considering dutasteride.
Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.
The conversation discusses using RU58841 mixed with topical minoxidil for hair loss, noting its chemical instability and storage challenges. A user shares their experience using RU58841 with ethanol and propylene glycol, mentioning no significant results yet.